Health Care·Life Sciences Tools & Services·$174.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $5.40 | N/A | +4.01% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $5.40 | N/A | +4.01% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed confidence in the company's ability to navigate current market conditions. They emphasized a focus on long-term growth despite economic uncertainties.
Management highlighted strong demand in key segments.
They noted ongoing investments in innovation and capacity expansion.
Thermo Fisher Scientific's earnings report shows a positive surprise in EPS, indicating better-than-expected profitability. The stock rose nearly 3% following the announcement, reflecting investor confidence in the company's performance. However, the lack of revenue data and forward guidance leaves some uncertainty about future growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KONINKLIJKE PHILIPS ADR
Jan 30, 2023